Co announces positive top-line results from it's Phase III clinical trial evaluating VEC-162, a balanced melatonin receptor agonist, in transient insomnia. VEC-162 demonstrated statistically significant improvements at all three tested doses compared to placebo in the primary endpoint of the trial, Latency to Persistent Sleep, a measure of sleep onset. VEC-162 also produced statistically significant improvements relative to placebo in Latency to Non-Awake, another measure of sleep onset, Wake After Sleep Onset, a measure of sleep maintenance, and Total Sleep Time. VEC-162 was also demonstrated to be safe and well-tolerated.